CLOVER BIO-B (02197) initiates phase 2 clinical trial for RSV - hMPV - PIV3 respiratory combined vaccine candidate product.

CLOVER BIO-B (02197) has announced that the Phase 2 clinical trials of their respiratory combined vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), developed based on the company's self-developed unique Trimer-Tag (protein trimerization) vaccine development platform and Pre-F trimer subunit recombinant protein, have completed the recruitment of the first batch of subjects in Australia and officially started. The Phase 2 clinical trials of Clover Bio's respiratory combined vaccine candidates in Australia is a randomized, observer-blinded, multicenter clinical trial designed to recruit up to 420 elderly subjects (60-85 years old). They will be randomly vaccinated with SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3), or placebo. The study will evaluate the safety, reactogenicity, and immunogenicity of the vaccines.